Membrane transporters in drug development
Open accessThe DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Abstract
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the human genome has been proven to have more than 400 membrane transporters, which are divided into two families: ATP binding cassette (ABC) and solute carrier (SLC) transporters [114].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Cited by
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Kim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734
An atlas of genetic influences on human blood metabolites
The Multiple Tissue Human Expression Resource (MuTHER) Consortium, Shin, S.-Y., Fauman, E. B., Petersen, A.-K., Krumsiek, J., Santos, R., Huang, J., Arnold, M., Erte, I., Forgetta, V., et al. (2014) · Nature Genetics · doi:10.1038/ng.2982 · Cited by 1,515
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationLöscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
BDDCS, the Rule of 5 and drugability
Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.007 · Cited by 892
Self-citation5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 876
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Self-citationDeuterium‐ and Tritium‐Labelled Compounds: Applications in the Life Sciences
Atzrodt, J., Derdau, V., Kerr, W. J., & Reid, M. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201704146 · Cited by 810
Chromone: A Valid Scaffold in Medicinal Chemistry
Gaspar, A., Matos, M. J., Garrido, J., Uriarte, E., & Borges, F. (2014) · Chemical Reviews · doi:10.1021/cr400265z · Cited by 760
Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation
Kim, H. J., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40126j · Cited by 750
Almazroo, O. A., Miah, M. K., & Venkataramanan, R. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.001 · Cited by 681
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Cobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Autophagy and multidrug resistance in cancer
Li, Y.-J., Lei, Y.-H., Yao, N., Wang, C.-R., Hu, N., Ye, W.-C., Zhang, D.-M., & Chen, Z.-S. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0219-2 · Cited by 665
SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1
Rebsamen, M., Pochini, L., Stasyk, T., de Araújo, M. E. G., Galluccio, M., Kandasamy, R. K., Snijder, B., Fauster, A., Rudashevskaya, E. L., Bruckner, M., et al. (2015) · Nature · doi:10.1038/nature14107 · Cited by 673
Coexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 649
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
“Transcellular transport can occur through various mechanisms (Lee et al., 2001; de Boer et al., 2003; Cecchelli et al., 2007; Ohtsuki and Terasaki, 2007; Ueno, 2009; Abbott et al., 2010; Giacomini et al., 2010), as illustrated in Figure 3.”
BackgroundABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Self-citationTransporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
A Call for Systematic Research on Solute Carriers
César-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 580
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
What do drug transporters really do?
Nigam, S. K. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4461 · Cited by 527
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective
Nigam, S. K., Bush, K. T., Martovetsky, G., Ahn, S.-Y., Liu, H. C., Richard, E., Bhatnagar, V., & Wu, W. (2015) · Physiological Reviews · doi:10.1152/physrev.00025.2013 · Cited by 502
Han, X., Huang, J., Lin, H., Wang, Z., Li, P., & Chen, Y. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701394 · Cited by 508
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Ohtsuki, S., Schaefer, O., Kawakami, H., Inoue, T., Liehner, S., Saito, A., Ishiguro, N., Kishimoto, W., Ludwig-Schwellinger, E., Ebner, T., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042259 · Cited by 434
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T., & Sugiyama, Y. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1823 · Cited by 418
Self-citationPrimovist, Eovist: What to expect?
Van Beers, B. E., Pastor, C. M., & Hussain, H. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.031 · Cited by 407
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationA guide to plasma membrane solute carrier proteins
Pizzagalli, M. D., Bensimon, A., & Superti‐Furga, G. (2021) · The FEBS Journal · doi:10.1111/febs.15531 · Cited by 379
Amorphous solid dispersions: Rational selection of a manufacturing process
Vasconcelos, T., Marques, S., das Neves, J., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.012 · Cited by 380
The SLCO (former SLC21) superfamily of transporters
Hagenbuch, B., & Stieger, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.009 · Cited by 385
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Karlgren, M., Vildhede, A., Norinder, U., Wisniewski, J. R., Kimoto, E., Lai, Y., Haglund, U., & Artursson, P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300212s · Cited by 369
The P-Glycoprotein Transport System and Cardiovascular Drugs
Wessler, J. D., Grip, L. T., Mendell, J., & Giugliano, R. P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.058 · Cited by 362
Drug Transporters in Drug Efficacy and Toxicity
DeGorter, M. K., Xia, C. Q., Yang, J. J., & Kim, R. B. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134529 · Cited by 359
Self-citationReversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor
Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.011 · Cited by 365
Hillgren, K. M., Keppler, D., Zur, A. A., Giacomini, K. M., Stieger, B., Cass, C. E., & Zhang, L. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.74 · Cited by 352
Self-citationTherapeutic applications of hydrogels in oral drug delivery
Sharpe, L. A., Daily, A. M., Horava, S. D., & Peppas, N. A. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.902047 · Cited by 354
Synergy effects of herb extracts: Pharmacokinetics and pharmacodynamic basis
Yang, Y., Zhang, Z., Li, S., Ye, X., Li, X., & He, K. (2014) · Fitoterapia · doi:10.1016/j.fitote.2013.10.010 · Cited by 333
Sex Differences in Drug Disposition
Soldin, O. P., Chung, S. H., & Mattison, D. R. (2011) · BioMed Research International · doi:10.1155/2011/187103 · Cited by 341
Budha, N. R., Frymoyer, A., Smelick, G. S., Jin, J. Y., Yago, M. R., Dresser, M. J., Holden, S. N., Benet, L. Z., & Ware, J. A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.73 · Cited by 338
Self-citationIntestinal drug transporters: An overview
Estudante, M., Morais, J. G., Soveral, G., & Benet, L. Z. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.042 · Cited by 330
Self-citationOrgan-on-a chip systems: microengineering to biomimic living systems
Zheng, F., Fu, F., Cheng, Y., Wang, C., Zhao, Y., & Gu, Z. (2016) · Small · doi:10.1002/smll.201503208 · Cited by 338
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Renal Transporters in Drug Development
Morrissey, K. M., Stocker, S. L., Wittwer, M. B., Xu, L., & Giacomini, K. M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140317 · Cited by 324
Self-citationTargeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Grimstein, M., Yang, Y., Zhang, X., Grillo, J., Huang, S.-M., Zineh, I., & Wang, Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.033 · Cited by 317
Self-citationPreclinical experimental models of drug metabolism and disposition in drug discovery and development
Zhang, D., Luo, G., Ding, X., & Lu, C. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.10.004 · Cited by 309
Demystifying Brain Penetration in Central Nervous System Drug Discovery: Miniperspective
Di, L., Rong, H., & Feng, B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301297f · Cited by 304
Kou, L., Bhutia, Y. D., Yao, Q., He, Z., Sun, J., & Ganapathy, V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00027 · Cited by 308
Chu, X., Bleasby, K., & Evers, R. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.741589 · Cited by 306
Self-citationDahan, A., & Miller, J. M. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9337-6 · Cited by 298
Cell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Organic Cation Transporters in Health and Disease
Koepsell, H. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015578 · Cited by 297
Foundations of gastrointestinal-based drug delivery and future developments
Chu, J. N., & Traverso, G. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00539-w · Cited by 289
The biology of ergothioneine, an antioxidant nutraceutical
Borodina, I., Kenny, L. C., McCarthy, C. M., Paramasivan, K., Pretorius, E., Roberts, T. J., van der Hoek, S. A., & Kell, D. B. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422419000301 · Cited by 296
Hepatic microcirculation and mechanisms of portal hypertension
Gracia-Sancho, J., Marrone, G., & Fernández-Iglesias, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 274
Loftsson, T., & Brewster, M. E. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01279.x · Cited by 286
Titanium Dioxide in the Service of the Biomedical Revolution
Rajh, T., Dimitrijevic, N. M., Bissonnette, M., Koritarov, T., & Konda, V. (2014) · Chemical Reviews · doi:10.1021/cr500029g · Cited by 293
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters
Nigam, S. K., Wu, W., Bush, K. T., Hoenig, M. P., Blantz, R. C., & Bhatnagar, V. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02440314 · Cited by 269
Andersson, T. B., Kanebratt, K. P., & Kenna, J. G. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.685159 · Cited by 259
Nies, A. T., Niemi, M., Burk, O., Winter, S., Zanger, U. M., Stieger, B., Schwab, M., & Schaeffeler, E. (2013) · Genome Medicine · doi:10.1186/gm405 · Cited by 265
Self-citationIn Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development
Brouwer, K. L. R., Keppler, D., Hoffmaster, K. A., Bow, D. A. J., Cheng, Y., Lai, Y., Palm, J. E., Stieger, B., & Evers, R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.81 · Cited by 267
Self-citationDrozdzik, M., Gröer, C., Penski, J., Lapczuk, J., Ostrowski, M., Lai, Y., Prasad, B., Unadkat, J. D., Siegmund, W., & Oswald, S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500330y · Cited by 258
Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
Bergström, C. A. S., Holm, R., Jørgensen, S. A., Andersson, S. B. E., Artursson, P., Beato, S., Borde, A., Box, K., Brewster, M., Dressman, J., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.10.015 · Cited by 257
Reese, M. J., Savina, P. M., Generaux, G. T., Tracey, H., Humphreys, J. E., Kanaoka, E., Webster, L. O., Harmon, K. A., Clarke, J. D., & Polli, J. W. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048918 · Cited by 254
Self-citationPochini, L., Scalise, M., Galluccio, M., & Indiveri, C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00061 · Cited by 249
Drug-Permeability and Transporter Assays in Caco-2 and Mdck Cell Lines
Volpe, D. A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.149 · Cited by 252
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K. L., Ballard, J., Cabalu, T., & Hochman, J. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9470-x · Cited by 248
Self-citationDifferent strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Kalantari, M., Mohammadinejad, R., Javaheri, T., & Sethi, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114002 · Cited by 248
Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1
Nosol, K., Romane, K., Irobalieva, R. N., Alam, A., Kowal, J., Fujita, N., & Locher, K. P. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010264117 · Cited by 245
Hellinger, É., Veszelka, S., Tóth, A. E., Walter, F., Kittel, Á., Bakk, M. L., Tihanyi, K., Háda, V., Nakagawa, S., Dinh Ha Duy, T., et al. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.07.020 · Cited by 237
Membrane transporters in drug development and as determinants of precision medicine
Galetin, A., Brouwer, K. L. R., Tweedie, D., Yoshida, K., Sjöstedt, N., Aleksunes, L., Chu, X., Evers, R., Hafey, M. J., Lai, Y., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00877-1 · Cited by 238
Self-citationCao, T., Zhang, W., Wang, Q., Wang, C., Ma, W., Zhang, C., Ge, M., Tian, M., Yu, J., Jiao, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.011 · Cited by 227
Jones, H. M., Barton, H. A., Lai, Y., Bi, Y.-A., Kimoto, E., Kempshall, S., Tate, S. C., El-Kattan, A., Houston, J. B., Galetin, A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042994 · Cited by 244
Erlinger, S., Arias, I. M., & Dhumeaux, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.047 · Cited by 244
Zamek‐Gliszczynski, M. J., Taub, M. E., Chothe, P. P., Chu, X., Giacomini, K. M., Kim, R. B., Ray, A. S., Stocker, S. L., Unadkat, J. D., Wittwer, M. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1112 · Cited by 231
Self-citationCrystal structure of a eukaryotic phosphate transporter
Pedersen, B. P., Kumar, H., Waight, A. B., Risenmay, A. J., Roe-Zurz, Z., Chau, B. H., Schlessinger, A., Bonomi, M., Harries, W., Sali, A., et al. (2013) · Nature · doi:10.1038/nature12042 · Cited by 235
Chen, L., Shu, Y., Liang, X., Chen, E. C., Yee, S. W., Zur, A. A., Li, S., Xu, L., Keshari, K. R., Lin, M. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314939111 · Cited by 237
Self-citationP-glycoprotein and its role in drug-drug interactions
Finch, A., & Pillans, P. (2014) · Australian Prescriber · doi:10.18773/austprescr.2014.050 · Cited by 230
Renal Drug Transporters and Drug Interactions
Ivanyuk, A., Livio, F., Biollaz, J., & Buclin, T. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0506-8 · Cited by 221
Zhang, Y., Wang, J., Bai, X., Jiang, T., Zhang, Q., & Wang, S. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200287c · Cited by 225
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J. (., Lee, T., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 225
The transport of antiepileptic drugs by P-glycoprotein
Zhang, C., Kwan, P., Zuo, Z., & Baum, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.003 · Cited by 225
Mendell, J., Zahir, H., Matsushima, N., Noveck, R., Lee, F., Chen, S., Zhang, G., & Shi, M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0029-0 · Cited by 223
Metadata
- Authors
- The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., Ware, J. A., Wright, S. H., Wah Yee, S., Zamek-Gliszczynski, M. J., & Zhang, L.
- Affiliations
- University of California, San Francisco (US)
- United States Food and Drug Administration (US)
- Boehringer Ingelheim (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Abbott (United States) (US)
- Eli Lilly (United States) (US)
- Novartis (United States) (US)
- RIKEN (JP)
- German Cancer Research Center (DE)
- Western University (CA)
- GlaxoSmithKline (United Kingdom) (GB)
- Genentech (US)
- University of Maryland, Baltimore (US)
- University of Arizona (US)
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-03
- Volume
- 9
- Issue
- 3
- Pages
- 215-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3326076
- OpenAlex
- W2079197876
- Cited by
- 3,340
- References
- 225
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 153 · 2023: 175 · 2022: 180 · 2021: 237 · 2020: 187 · 2019: 219 · 2018: 234 · 2017: 216 · 2016: 242 · 2015: 233 · 2014: 248 · 2013: 316 · 2012: 254
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- National Institutes of Health (GM61390)
- U.S. Food and Drug Administration
- National Institute of General Medical Sciences (GM61390, R01GM041935, U19GM061390, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080801, R01DK061425)
- National Institute of Environmental Health Sciences (P30ES006694)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- membrane transporters, drug transporters, drug-drug interactions, pharmacokinetics, drug absorption, drug disposition, drug development, drug safety and efficacy, drug labeling
- MeSH terms
- Animals, Computer Simulation, Decision Trees, Drug Interactions, Drug Evaluation, Preclinical, Humans, Drug Approval, Mice, Knockout, Membrane Transport Proteins, Mice, Prescription Drugs, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.